Evaluation of a Commercial Rapid Molecular Point-of-Care Assay for Differential Diagnosis Between SARS-CoV-2 and Flu A/B Infections in a Pediatric Setting DOI Creative Commons
Paolo Bottino, Costanza Massarino, Christian Leli

et al.

Viruses, Journal Year: 2024, Volume and Issue: 16(10), P. 1638 - 1638

Published: Oct. 20, 2024

Given the ongoing COVID-19 pandemic, there is a need to identify SARS-CoV-2 and differentiate it from other respiratory viral infections, especially influenza A B, in various critical settings. Since their introduction, use of rapid antigen tests has spread worldwide, but variability diagnostic accuracy. In present study, we evaluated clinical performance ID NOW™ 2.0, molecular point-of-care test (POCT) based on enzymatic isothermal amplification for differential diagnosis A/B pediatric emergency setting. cohort patients admitted between December 2022 February 2023 were simultaneously tested with POCT standard laboratory assay. Our findings showed high negative agreement assay across different age groups SARS-CoV-2, A, B (more than 98.0%), while its positive varied significantly abovementioned species 50.0% 100%. These results highlight potential 2.0 as reliable tool excluding infections symptomatic patients, although variable suggests confirmatory RT-qPCR testing certain epidemiological settings order ensure accurate appropriate patient management.

Language: Английский

SARS-CoV-2 Vaccines, Vaccine Development Technologies, and Significant Efforts in Vaccine Development during the Pandemic: The Lessons Learned Might Help to Fight against the Next Pandemic DOI Creative Commons
Chiranjib Chakraborty, Manojit Bhattacharya, Kuldeep Dhama

et al.

Vaccines, Journal Year: 2023, Volume and Issue: 11(3), P. 682 - 682

Published: March 17, 2023

We are currently approaching three years since the beginning of coronavirus disease 2019 (COVID-19) pandemic. SARS-CoV-2 has caused extensive disruptions in everyday life, public health, and global economy. Thus far, vaccine worked better than expected against virus. During pandemic, we experienced several things, such as virus its pathogenesis, clinical manifestations, treatments; emerging variants; different vaccines; development processes. This review describes how each been developed approved with help modern technology. also discuss critical milestones during process. Several lessons were learned from countries two research, development, trials, vaccination. The process will to fight next

Language: Английский

Citations

64
Clinical and laboratory diagnosis of monkeypox (mpox): Current status and future directions DOI Creative Commons
Severino Jefferson Ribeiro da Silva, Alain Kohl, Lindomar Pena

et al.

iScience, Journal Year: 2023, Volume and Issue: 26(6), P. 106759 - 106759

Published: April 28, 2023

The emergence and rapid spread of the monkeypox virus (MPXV) to non-endemic countries has brought this once obscure pathogen forefront global public health. Given range conditions that cause similar skin lesions, because clinical manifestation may often be atypical in current mpox outbreak, it can challenging diagnose patients based on signs symptoms. With perspective mind, laboratory-based diagnosis assumes a critical role for management, along with implementation countermeasures. Here, we review features reported patients, available laboratory tests diagnosis, discuss principles, advances, advantages, drawbacks each assay. We also highlight diagnostic platforms potential guide ongoing response, particularly those increase capacity low- middle-income countries. outlook evolving research area, hope provide resource community inspire more development alternatives applications future health crises.

Language: Английский

Citations

33
Green and efficient one-pot three-component synthesis of novel drug-like furo[2,3-d]pyrimidines as potential active site inhibitors and putative allosteric hotspots modulators of both SARS-CoV-2 MPro and PLPro DOI Open Access
Hossein Mousavi, Behzad Zeynizadeh, Mehdi Rimaz

et al.

Bioorganic Chemistry, Journal Year: 2023, Volume and Issue: 135, P. 106390 - 106390

Published: Jan. 28, 2023

Language: Английский

Citations

27
Genetic susceptibility to severe COVID-19 DOI Creative Commons
Claudio Cappadona, Valeria Rimoldi, Elvezia Maria Paraboschi

et al.

Infection Genetics and Evolution, Journal Year: 2023, Volume and Issue: 110, P. 105426 - 105426

Published: March 17, 2023

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiologic agent of disease 2019 (COVID-19) pandemic. Clinical manifestations range from an asymptomatic condition to life-threatening events and death, with more severe courses being associated age, male sex, comorbidities. Besides these risk factors, intrinsic characteristics virus as well genetic factors host are expected account for COVID-19 clinical heterogeneity. Genetic studies have long been recognized fundamental identify biological mechanisms underlying congenital diseases, pinpoint genes/proteins responsible susceptibility different inherited conditions, highlight targets therapeutic relevance, suggest drug repurposing, even clarify causal relationships that make modifiable some environmental factors. Though usually take time be concluded and, above all, translate their discoveries patients' bedside, scientific community moved really fast deliver signals phenotypes. In this Review, besides a concise description symptomatology SARS-CoV-2 mechanism infection, we aimed recapitulate current literature in terms specifically associate increased severity disease.

Language: Английский

Citations

26
The Second Life for Unused COVID-19 Vaccines: Towards Biosensing Application DOI
Vincentas Mačiulis, Asta Lučiūnaitė,

Mantvydas Usvaltas

et al.

Talanta, Journal Year: 2025, Volume and Issue: unknown, P. 127647 - 127647

Published: Jan. 1, 2025

Language: Английский

Citations

1
Development of an Innovative Three-Component Optical Resolution and a Flow Chemistry Process for (R)-Troloxamide Quinone (EPI-589) DOI
Hirotsugu Usutani,

Kiichi Kuroda,

Kazuhiro SAWAMURA

et al.

Organic Process Research & Development, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 25, 2025

Language: Английский

Citations

1
Detection of COVID-19: A Smartphone-Based Machine-Learning-Assisted ECL Immunoassay Approach with the Ability of RT-PCR CT Value Prediction DOI
Ali Firoozbakhtian, Morteza Hosseini, Mahsa Sheikholeslami

et al.

Analytical Chemistry, Journal Year: 2022, Volume and Issue: 94(47), P. 16361 - 16368

Published: Nov. 16, 2022

The unstoppable spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has severely threatened public health over the past years. current ubiquitously accepted method for its diagnosis provides sensitive detection virus; however, it is relatively time-consuming and costly, not to mention need highly skilled personnel. There a clear develop novel computer-based diagnostic tools provide rapid, cost-efficient, time-saving in places where massive traditional testing practical. Here, we an electrochemiluminescence (ECL)-based system whose results are quantified as reverse transcriptase polymerase chain reaction (RT-PCR) cyclic threshold (CT) values. A concentration-dependent signal generated upon introduction virus electrode recorded with smartphone camera. ECL images used train machine learning algorithms, model using artificial neural networks (ANNs) 45 samples was developed. demonstrated more than 90% accuracy 50 unknown real samples, detecting up CT value 32 limit (LOD) 10–12 g mL–1 samples.

Language: Английский

Citations

35
Food Plant Secondary Metabolites Antiviral Activity and Their Possible Roles in SARS-CoV-2 Treatment: An Overview DOI Creative Commons
Deborah Giordano, Angelo Facchiano, Virginia Carbone

et al.

Molecules, Journal Year: 2023, Volume and Issue: 28(6), P. 2470 - 2470

Published: March 8, 2023

Natural products and plant extracts exhibit many biological activities, including that related to the defense mechanisms against parasites. Many studies have investigated functions of secondary metabolites reported evidence antiviral activities. The pandemic emergencies further increased interest in finding agents, efforts are oriented investigate possible activities human viruses their potential application treating or preventing SARS-CoV-2 infection. In this review, we performed a comprehensive analysis through silico vitro investigations, also vivo applications clinical trials, evaluate state knowledge on infection, with particular focus natural compounds present food plants. Although some seem be useful prevention as therapeutic management SARS-CoV-2, up now, no molecules can used treatment for COVID-19; however, more research is needed.

Language: Английский

Citations

17
Higher Omicron JN.1 Coronavirus Transmission due to Unique 17MPLF Spike Insertion compensating 24LPP, 69HV, 145Y, 211N and 483V deletions in the spike DOI Creative Commons
Asit Kumar Chakraborty

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: Jan. 4, 2024

Abstract The COVID-19 Spike protein 24 LPP, 69 HV, 143 VYY, 156 FR, 212 L deletions, 215 EPE and 249 RWMD insertions were very well characterized. Changes in spike likely select RBD a favorable 3-D structure to interact with ACE-2 receptor of human cells for coronavirus entry. Our goal is characterize the newly spreading JN.1 subvariant related omicron coronaviruses. BLASTP search found 17 MPLF four amino acid insertion BA.2.86 its precedent which had unique L452S (L455 Wuhan) mutation. variant also contained 2375 SGF deletion ORF1ab, 145 Y, 211 N ( 208 BA.2) 483 V 480 deletions spike, 31 ERS N-protein 26nt 3’-UTR (NC_045512.2). Many mutations (242N = H249N, 261D A268D, 352T K360T, 400K R407K, 442H P449H, 449W L456W, 474K N485K, 480K A488K 566V A574V) might be important. BLASTN oligo over 3895 sequences NCBI Database distributed America Europe but more monopartite deposited from Europe. Although, acquired HV lately did not generated BA.4 or BA.5 lineages it was solely variant. Swiss-Model detected wing basic middle tripartite important first interacting surface acids changed. small M D3H, A63T A104V Swiss Model showed no gross change structure. Further, specific ORF1ab polyprotein detected: T170I mutation nsp1 as D1600N, K1973R nsp3 protease R3821K nsp6. Astonishingly, after long journey XBB.1.5.1 XBB.1.5.100 subvariants spread, sudden five 176 EGKEG 180 EGKQG XBB.1.5.103 found. ORF8 immune-regulatory expression abolished all XBB.1 including XBB.1.16.23 expected due termination codon (AAA TAA, CAA GGA TGA). But such gene (GGA TGA) ongoing dominated JD.1.1, FL.1.5.1, HV.1 EG.5.1.1 subvariants, derived lineage. FL.1.5.1 has 82 GHV instead GHVMV 27nt (27887 5’-aac gaa cat att tct tgt ttt ctt-3’) ORF7a gene. Partial nsp1, regulatory proteins cause immune deficient less pathogenic. spread sent an alarm among health officials worldwide. It worthwhile see if goes OR7a time lowering pathogenicity.

Language: Английский

Citations

7
Computer-aided drug design of novel nirmatrelvir analogs inhibiting main protease of Coronavirus SARS-CoV-2 DOI Open Access
Kateryna Lohachova,

Anastasiia S . Sviatenko,

Alexander Kyrychenko

et al.

Journal of Applied Pharmaceutical Science, Journal Year: 2024, Volume and Issue: unknown

Published: Jan. 1, 2024

A computer-aided drug design of new derivatives nirmatrelvir, an orally active inhibitor the main-protease (Mpro) severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2), was performed to identify its analogues with a higher antiviral potency. The following workflow used: first, evolutionary library composed 1,866 generated starting from parent nirmatrelvir scaffold and going through small mutation, fitness scoring, ranking, selection. Second, preprocessed filtered against 3-D pharmacophore model built X-ray structure in co-crystalized complex Mpro enzyme, allowing us reduce chemical space 32 analogues. Third, structure-based molecular docking two different enzyme structures further ranked these candidates, so that up eight better-binding analogs were identified. selected hit-analogues target enzymes SARS-CoV-2 binding affinity than nirmatrelvir. main structural modifications increase overall inhibitory are identified at azabicyclo[3.1.0] hexane 2-oxopyrrolidine fragments. characteristic feature centre is similar location trifluoroacetylamino fragment, which observed for most hit-analogues. suggested rational noncovalent inhibitors based on approved drugs promising, extremely low-cost, time-efficient approach development potential pharmaceutical ingredients treatment Disease 2019.

Language: Английский

Citations

6